aTyr Pharma Inc ATYR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma Announces One-for-40 Reverse Stock Split
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Trading Information
- Previous Close Price
- $3.69
- Day Range
- $3.80–4.15
- 52-Week Range
- $3.69–44.40
- Bid/Ask
- $3.80 / $4.72
- Shares Outstanding
- 2.55M
- Market Cap
- $9.74M
- Volume/Avg
- 91,028 / 112,543
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
- Website
- https://www.atyrpharma.com
Valuation
Metric | ATYR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.28 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ATYR |
|---|---|
Quick Ratio | 3.00 |
Current Ratio | 3.05 |
Interest Coverage | — |
Quick Ratio
ATYR
Profitability
Metric | ATYR |
|---|---|
Return on Assets (Normalized) | −57.55% |
Return on Equity (Normalized) | −81.60% |
Return on Invested Capital (Normalized) | −68.07% |
Return on Assets
ATYR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#w@!$wK | LOCK|!!l> | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|fsMFc@y | LOCK|Fw%%? | $95B | |||
| Moderna Inc MRNA | LOCK|lGGpTYS | LOCK|$> | $79B | |||
| argenx SE ADR ARGX | LOCK|JlGt!F | LOCK|?# | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?$#bhF | LOCK|x& | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|LM^&t@$w | LOCK|VZn&M | $30B | |||
| Incyte Corp INCY | LOCK|^TNHM% | LOCK|Jx | $23B | |||
| BioNTech SE ADR BNTX | LOCK|<%H>!% | LOCK|hM | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@hmWc@# | LOCK|L!jwF | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|g^L?SZG | LOCK|gf | $15B |